» Articles » PMID: 11586430

Preliminary Analysis of Sm14 in Distinct Fractions of Schistosoma Mansoni Adult Worm Extract

Overview
Date 2001 Oct 5
PMID 11586430
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In previous studies it was shown that the recombinant molecule, r-Sm14, induces high levels of protection against Schistosoma mansoni infection in two outbred animal models and immune crossprotection against infection by Fasciola hepatica in Swiss outbred mice. r-Sm14 was derived from a living worm extract, called SE, and is being developed as the molecular basis of an anti-helminth bivalent vaccine against the two parasites, for medical and veterinary application. Present data refer to SDS-PAGE and Western Blotting analysis of four different preparations of S. mansoni adult worms focusing Sm14 identification. The extracts correspond to the initial fraction of the SE extraction process, containing products released by living worms (SEi); SE2, reextraction of adult worms in PBS; and SE of separated male and female adult worms. In all extracts it was possible to detect the component of 14 kDa, that was recognized by specific anti-rSm14 antibody raised in rabbits.

Citing Articles

Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.

Panzner U, Excler J, Kim J, Marks F, Carter D, Siddiqui A Front Trop Dis. 2024; 2.

PMID: 39280170 PMC: 11392908. DOI: 10.3389/fitd.2021.719369.


Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development.

Molehin A Res Rep Trop Med. 2020; 11:119-128.

PMID: 33173371 PMC: 7646453. DOI: 10.2147/RRTM.S274518.


Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity.

Smole U, Gour N, Phelan J, Hofer G, Kohler C, Kratzer B Nat Immunol. 2020; 21(7):756-765.

PMID: 32572240 PMC: 9291269. DOI: 10.1038/s41590-020-0698-1.